INFLUENZA IN CHILDREN

BY DR. VISHAL MEHTA RAKHOSPITAL

Conflicts of Interest- None Disclosures- None

Learning Outcomes

At the end of the presentation, the delegates will be able to -

- Understand the microbiology & pathogenesis of influenza virus
- Formulate the treatment plan
- Underatand Prophylaxis & infection control measures
- Enumerate the vaccines available

- 5 months old male child (7kg) brought with
- Fever for 5 days
- cold and cough for 3 days &
- Breathing difficulty for 2 days
- Blood C/S & other investigations sent and started on broad spectrum antibiotics
- fever & distress persisting after 3 days of admission



- CFT <3 Sec, Temp 38 C
- HR-166/Min RR 68/min
- SPO2 96% In Room air
- RS- Occasional Crepts + / SCR +
- Hemogram WNL
- QBC & Widal Negative
- ICT Scrub Typhus Negative
- CXR Hyperinflation + Mild B/L
 Insignificant Infiltrates
- CRP Negative

- Probable diagnosis ?
- Investigations ?
- if positive,
- •Clinical category ?
- Drug of choice ? dose ?
- Supportive measures ?
- If child worsens even after 5 days of drug intake, what you do ?
- If symptoms resolved, how long the organisms shed from this child ?


ETIOLOGY

- Importance of Influenza
- •One of the most important **Emerging** and **Reemerging** infectious diseases
- •Causes high morbidity and mortality in communities (epidemic) and worldwide (pandemic)
- •Epidemics are associated with excess mortality

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902.

Causative Agent Of Influenza

Large single stranded RNA virus
Orthomyxoviridae
Includes 3 genera




Influenza virus A Primary human pathogens, Influenza virus B causing seasonal epidemics Influenza virus C Sporadic (URI symptoms)

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902.

Classification of influenza virus

- Type A viruses are divided into subtypes
- Based on viral surface proteins or antigens
 Hemagglutinin (H)
 Reason for antigenic variation in
 type A Neuraminidase (N)
- Type B & C
 No such subtype
 designation So less
 antigenic variation

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902.



Classification of influenza virus


Classified on the basis of hemagglutinin (HA) and neuraminidase (NA)

18 subtypes of HA and 11 subtypes of NA are known to exist in animals (HA 1-18, NA 1-11)

3 subtypes of HA (1-3) and 2 subtypes of NA (1-2) are human influenza viruses.

HA 5, 7, 9 and NA 7 can also infect humans

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902.



EPIDEMIOLOGY

- Person to person
- Droplet infection (sneezing & coughing or talking)
- The portal of entry of the virus is the respiratory tract.
- IP 12 72 hours
- Seasonal influenza

colder months in temperate climates

- Four major global epidemics
 - 1918 A(H1N1) most severe
 - 1957 A(H2N2)
 - 1968 A(H3N2)
 - 2009 A(H1N1)pdm09

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902.

Mode of transmission in human

- The virus is spread from person-to-person through respiratory secretions either as droplets (close contact) or as airborne infection by droplet nuclei suspended in the air.
- Incubation period 1-3 days


Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902.

GENETICS

Genetic drift

Influenza a & b has genome with 8 single strand RNA segments

- Minor changes within the subtyped
- Point mutation
- HA gene (predominantly)
- So new influenza strains of same HA type
- Can occur in both type A & B
- Occurs yearly




GENETICS

Genetic shift


- Major changes in subtype
- Less frequent more dramatic
- Reassortment of viral segments
- Simultaneous infection by more than single host
- Emergence of novel subtypes
 Avian influenza A (H5N1) in 1997 in 13
 counties avian influenza A (H7N9) in
 2013 in china
- Influenza A
- Avian & mammalian hosts

III III	1 PLACE	CIEL In a grant and		
II II		_	21	er.
(* *******	The state of the s	/		TIN
La La	Terre		-	




Antigenic shift [pandemics]

Gene reassortment leading to altered surface proteins and antigenic profile



Newly created subtype




Antigenic drift

Small gene mutations/changes leading to altered antibody-binding sites and escape from immunity.

PATHOGENESIS


- Respiratory tract
 - Invades ciliated columnar epithelium
 - Using HA to sialic residues
- Replication occurs within 4 6 hours, then
- Infectious viruses produced and
- Released into neighbouring cells
- Replication continues for 10 14 days
- Lytic infection of respiratory epithelium
- Loss of ciliary function
- Decreased mucous production
- Desquamation

Secondary bact. infection



SIGNS & SYMPTOMS

- Fever (100 F-103 F in adults and often even higher in children)
- Chills
- Cough
- Sore throat
- Runny or stuffy nose
- Headache
- Muscle aches
- Extreme fatigue
- Anorexia



 Abdomen pain, vomiting and loose stools also can occur in children

Clinical Diagnosis

✓ The clinical picture of influenza is nonspecific.

- Influenza-like illness can be caused by many microbial agents other than influenza virus, such as
 - Adenovirus,
 - Parainfluenza Viruses,
 - Coronavirus,
 - Mycoplasma Pneumoniae,
 - Chlamydia Pneumoniae,
 - Beta-hemolytic Streptococcus.

CLINICAL CATEGORISATION

CATEGORY A

- Mild fever + cough / sore throat with or without
- Body ache, headache, diarrhoea and vomiting
- Oseltamivir not needed
- Symptomatic treatment.
- Monitor for progress and reassess at 24 to 48 hours
- H1N1 test not required.
- Should confine themselves at home and avoid mixing up.



CLINICAL CATEGORISATION

CATEGORY-B

CATEGORY A + high grade fever and severe sore throat

- Require home isolation and oseltamivir
- CATEGORY A + following high risk conditions shall be treated with oseltamivir
 - Pregnant women
 - Very young or very old age
 - Systemic diseases, blood disorders, neurological disorders & diabetes
 - Cancer and HIV/AIDS
 - Long term cortisone therapy.

• H1N1 test

- Should confine themselves at home and avoid mixing up
- Broad spectrum antibiotics as per the guideline for CAP

CLINICAL CATEGORISATION

CATEGORY-C

• CATEGORY A AND B + one or more of the following:

•	Breathlessness	Chest pain
•	Drowsiness	Fall in blood pressure
•	Sputum mixed with blood	Bluish discolouration of nails

- Children with influenza like illness + previous severe disease, manifests with
 - Somnolence High and persistent fever
 Inability to feed well convulsions
 Shortness of breath Difficulty in breathing
- Worsening of underlying chronic conditions.
- Category-c require testing, immediate hospitalization and treatment.

INVESTIGATIONS

- Routine baseline investigations
- Confirmation of H1N1
 - Real time RT PCR or "
 - Isolation of the virus in culture or "
 - Four-fold rise in virus specific neutralizing antibodies
- Clinical specimens are
 - Nasopharyngeal swab
 - Throat swab
 - Nasal swab
 - Tracheal aspirate (for intubated patients)

Contd.,

- Collect before administration of the anti-viral drug.
- Keep specimens at 4°c in viral transport media until transported.
- Should be transported within 24 hours.
- If not, should be stored at -70°c.
- Paired blood samples for serological testing

PHARMACOLOGICAL TREATMENT

OSELTAMIVIR

- NA inhibitor
- Can be given as young as 2 weeks of life
- Used in both prophylaxis and treatment
- Age >1 year
 - <15kg 30 mg BD for 5 days
 - 15-23kg 45 mg BD for 5 days
 - 24-<40kg- 60 mg BD for 5 days
 - >40kg- 75 mg BD for 5 days
- Age <1 year
 - < 3 months 12 mg BD for 5 days</p>
 - 3-5 months 20 mg BD for 5 days
 - 6-11 months 25 mg BD for 5 days
- Transient nausea and vomiting are the common side effects

Oral oseltamivir treatment of influenza in Children. Richard J. Pediatr Infect Dis J, 2001;20:127–33.

Contd.,

ZANAMIVIR

- NA inhibitors
- Used in OSELTAMIVIR resistant cases
- Available in inhalational and IV preparations
- Recommended in age 7 years and older
- Treatment

10 mg twice daily (two 5mg inhalations) for 5days

Prophylaxis

10 mg once daily (two 5mg inhalations) for 5days

SUPPORTIVE TREATMENT

- S Salicylate/aspirin contraindicated (risk of Reye syndrome) Secondary bacterial infection control
- U Euglycemia / Euthermia
- P Paracetamol / Ibuprofen for fever and myalgia
- P Parenteral nutrition
- O Oxygen support (depends upon the requirement)
- R Resuscitation (ABC) / Rest Radiological monitoring of lungs
- T Throat and nasal care
- I IV Fluids/Hydration
- V Vasopressors for shock
- E Electrolyte balance

DISCHARGE POLICY

- Responded in 2 or 3 days and become asymptomatic
 - Discharge after 5 days of treatment.
 - No need for a repeat test.

- Patients who continue to have symptoms on the 5th day
 - Continue treatment for 5 more days
 - If asymptomatic during treatment, no test needed

Contd.,

- Symptomatic after 10 days of treatment or / respiratory distress
 - Secondary infection must be taken care
 - Resistance of anti viral would be tested
 - The dose of anti viral may be adjusted on case to case basis
- Family of patients discharged earlier should be educated on
 - Personal hygiene
 - Infection control measures at home
 - Children's abstinence from school

CHEMOPROPHYLAXIS

For health care workers of isolation unit

- Treating physicians
- Paramedical personnel
- Unit helpers
- Oseltamivir 75 mg OD for 10 days

For contacts

- High risk patients
 - With under lying systemic diseases
 - Extremes of age < 5 years and >65 years

CHEMOPROPHYLAXIS DOSAGE

- Oseltamivir is the drug of choice.
- For 10 days after last exposure
- Age >1 year
 - <15kg 30 mg OD for 10 days</p>
 - 15-23kg 45 mg OD for 10 days
 - 24-<40kg 60 mg OD for 10 days
 - >40kg 75 mg OD for 10 days
- Age <1 year
 - < 3 months</p>

Not recommended unless judged critical Limited studies

- 3-5 months 20 mg OD for 10 days
- 6-11 months 25 mg OD for 10 days

PPE(PERSONAL PROTECTIVE EQUIPMENT)

PPE reduces the risk of infection if used correctly

- Gloves (non sterile)
- Mask (high-efficiency mask)
- Three layered surgical mask
- Long-sleeved cuffed gown
- Protective eyewear (goggles/visors/face shields)
- Cap (increased aerosols)



• Plastic apron if splashing of secretions are anticipated. Recommendations for Prevention and Control of Influenza in Children, 2019–2020. COMMITTEE ON INFECTIOUS DISEASES. Pediatrics, Oct 2019;144 (4)

PPE APPLYING ORDER

- Follow thorough hand wash
- Wear the coverall
- Wear the goggles/ shoe cover/and head cover in that order.
- Wear face mask
- Wear gloves

The masks should be changed after every six to eight hours.



PPE REMOVING ORDER

- Remove gloves
- Remove gown
- Wash hands with soap and water
- Remove cap and face shield
- Remove mask

By grasping elastic behind ears do not touch front of mask

Wash hands with soap and water

before leaving the room



INFECTION CONTROL MEASURES

ISOLATION UNIT

- The patient should wear a three layer surgical mask.
- The medical/paramedical personnel should wear PPE
- Water proof apron, if soiling anticipated.
- Avoid aerosol-generating procedures
- Perform hand hygiene
- Infection control precautions to continue
 - Adult patient for 7 days after resolution of symptoms
 - Children <12 for 14 days after resolution of symptoms
- Disinfection of contaminated surfaces and equipments
 - On daily basis
 - Once after discharge



Contd.,

DURING TRANSPORT

- Patient should also wear a three layer surgical mask
- Avoid aerosol generating procedures
- Ambulance cabin personnel should wear
 - Full complement of PPE + N95 masks
- Driver should wear three layered surgical mask
- Once the patient is admitted to the hospital
 - Interior/exterior of the ambulance
 - Reusable patient care equipment needs to be sanitized
- Standard disposal of waste (including PPE) in ambulance

Types of Vaccine

Inactivated, consisting of

(1) whole-virus,
(2) subvirion,
(3) purified surface antigen.
Only subvirion or purified antigen should be used in children.
Any of the three can be used for adults.

Live attenuated

Vaccine

Inactivated influenza vaccine (IIP)(Trivalent)

- Killed influenza virus component is used
- Three strains are used
 - Influenza A (H1N1) virus
 - Influenza A (H3N2) virus
 - Influenza B virus.
- Antibodies will develop two weeks after vaccination.
- IM route
- Protective efficacy is 50 to 60 %
- Excellent safety profile

Contd.,

- Recommended after 6 completed months
- 6 months to 3 years 0.25ml / 2 doses / 4 weeks apart / per year
- >3 years 0.5 ml / one or 2 dose / per year
- Soreness, redness and tenderness over injection site are common SE
- CI in children who are at higher risk of developing complications

https://www.cdc.gov/flu/about/qa/vaccineeffect.htm

References

- Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902.
- The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in Children. Kathleen Maletic Neuzil N Engl J Med 2000; 342:225-231.
- Oral oseltamivir treatment of influenza in Children. Richard J. Pediatr Infect Dis J, 2001;20:127–33.
- Recommendations for Prevention and Control of Influenza in Children, 2019–2020. COMMITTEE ON INFECTIOUS DISEASES. Pediatrics, Oct 2019;144 (4)

